Sign up
Pharma Capital

Scientists make major breakthrough with ANGLE’s Parsortix liquid biopsy system

It had previously been thought that brain cancers couldn’t be traced by ANGLE’s Parsortix system, but a team of Scientists has disproved that theory
blood
Parsortix works by detecting and capturing circulating tumour cells in the bloodstream

Researchers have shown that ANGLE PLC’s (LON:AGL) Parsortix liquid biopsy system can be used to identify people with glioblastoma – an aggressive type of brain cancer.

Parsortix detects and captures circulating tumour cells (CTCs), which provide the tell-tale signs of cancer and their capture can allow doctors to more accurately assess treatment options.

READ: ANGLE on track to conclude FDA study by year-end

It had previously been thought that clusters of CTCs in brain cancers would not pass through the blood-brain barrier meaning ANGLE’s system wouldn’t have been able to detect them.

But a team of scientists from the University of Basel in Switzerland has disproved that theory, showing that as well as singular CTCs, clusters of CTCs will pass through the blood-brain barrier and can be harvested for analysis using the Parsortix system.

“The glioblastoma work is a further example of ground breaking research being undertaken by a Parsortix customer in addition to ANGLE's own efforts to commercialise the Parsortix system,” said chief executive Andrew Newland.

“University of Basel and their collaborators are working on the application of this approach for the treatment of glioblastoma patients and we look forward to reporting further developments in due course.”

Shares rose 5.2% in early deals on Tuesday to 48.9p.

View full AGL profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.